## Edgar Filing: AMGEN INC - Form 4

AMGEN IN Form 4													
August 07, 2	ЛЛ									OMB AF	PPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287				
Check this box if no longer subject to Section 16. Section 16.				ANGES IN BENEFICIAL OWNERSHIP O SECURITIES						Expires: Estimated a burden hou	irs per		
Form 4 of Form 5 obligatio may com <i>See</i> Instr 1(b).	Filed pur ons stinue. Section 17(	a) of the l	Public U	tility	Hol	ding Co	mpar	•	Act of 1934, 1935 or Section )	response	0.5		
(Print or Type	Responses)												
Patton Cynthia M Sy				2. Issuer Name <b>and</b> Ticker or Trading Symbol AMGEN INC [AMGN]					5. Relationship of Reporting Person(s) to Issuer				
(Last)	(Last) (First) (Middle) 3. Date of					ransactior	1		(Check all applicable)				
ONE AMG	EN CENTER DF	RIVE	(Month/I 08/05/2	-	ar)			·	Director X Officer (give below) SV		o Owner er (specify		
THOUSAN			4. If Am Filed(Mo			ate Origin r)	al		6. Individual or Joi Applicable Line) _X_ Form filed by O Form filed by M Person	ne Reporting Pe	erson		
	(State)	(7:0)											
(City)	(State)	(Zip)			on-l			-	ired, Disposed of,		•		
1.Title of Security (Instr. 3)	curity (Month/Day/Year) Execution Date, if			Code (Instr. 3, 4 and 5)					Securities Beneficially Owned Following Reported Transaction(s)	6.7. Nature ofOwnershipIndirectForm:BeneficialDirect (D)Ownershipor Indirect(Instr. 4)(I)(Instr. 4)			
Common				Code	V	Amount	(D)	Price	(Instr. 3 and 4)				
Common Stock	08/05/2014			М		920	А	\$ 58.43	19,154	D			
Common Stock	08/05/2014			Μ		1,724	А	\$ 54.69	20,878	D			
Common Stock	08/05/2014			S		2,644	D	\$ 127.972 (1)	18,234 <u>(2)</u> <u>(3)</u>	D			
Common Stock									233.5433 <u>(4)</u>	Ι	401(k) Plan		

### Edgar Filing: AMGEN INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nqso (Right to Buy)	\$ 58.43	08/05/2014		М		920	04/26/2013	04/26/2020	Common Stock	920
Nqso (Right to Buy)	\$ 54.69	08/05/2014		М		1,724	04/25/2013	04/25/2021	Common Stock	1,724

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships						
<b>r</b> g	Director	10% Owner	Officer	Other			
Patton Cynthia M ONE AMGEN CENTER DRIVE THOUSAND OAKS, CA 91320-1799			SVP & CCO				
Signatures							
/s/ Andrea Robinson, Attorney-in-Fact Patton	for Ms.	0	8/07/2014				
<u>**</u> Signature of Reporting Person			Date				

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price reported is an average price. The prices ranged from \$126.62 to \$129.00 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

8 D S (]

### Edgar Filing: AMGEN INC - Form 4

These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,000 RSUs which fully vest on 10/28/2014; 508 RSUs which vest in on 4/25/2015; 804 RSUs which vest in two annual installments of 396 on 4/27/2015 and 408

(2) on 4/27/2016; 5,420 RSUs which vest in three installments of 1,788, 1,789 and 1,843 on 10/26/2014, 10/26/2015 and 10/26/2016, respectively; 2,103 RSUs which vest in three installments of 693, 694 and 716 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively; and 1,092 RSUs which vest in two equal installments of 360 on 1/31/2016 and 1/31/2017 and one installment of 372 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

These shares include 284 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in

- (3) Fran and subject to a quantying dividend reinvestment plan. Des are created on the reporting person's unvested KSUs and are paid out if shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- (4) These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.